





Annual Report 2025


Table of Contents



01 Message from Director



02 Who are we




03 Our Institutional Partners




04 Registry




05 Research




06 Publications




07 Education & Training: Nursing Webinars




08 Training of Data Entry Operators




09 Patient Advocacy Group



10 Fifth Annual Meet



11 Financial Report




12 Connect with us



Message from Director

Dear Friends, Colleagues, and Partners,
As we reflect on the past year at the Hematology Cancer Consortium (HCC), we take pride in the continued growth of our collaborative network and the progress we have made towards improving outcomes for patients with hematological cancers across India.



In 2025, HCC expanded to 36 institutional partners, with 43,333 records across seven disease-specific registries, further strengthening our shared data and research platform. Our Disease Working Groups continued to foster collaboration and support the development of evidence-based approaches to clinical care and research.

We were also pleased to have five HCC studies accepted for presentation at the 2025 Annual Meeting of the American Society of Hematology (ASH) and one study published in the Blood Cancer Journal in 2025, marking an encouraging step forward in HCC's growing academic and scientific contributions.

Education and capacity building remained an important focus. By December 2025, we had conducted 49 nursing webinars, supporting continued professional development and knowledge exchange across participating centres. Our Patient Support Group, launched in 2023, completed 30 monthly sessions, providing an important platform for patient engagement, support, and the sharing of experiences.

A major highlight of the year was the 5th HCC Annual Meeting, held from 3–5 October 2025 at NCI-AIIMS, Jhajjar, in association with RESMO. With the theme, “Evidence-Based and Context-Driven Best Practices for Treatment of Hematological Cancers,” the meeting brought together clinicians, nurses, trainees, researchers, pathologists, data teams, patients, and international faculty for meaningful discussions and knowledge exchange.

We are especially grateful to the National Cancer Grid (NCG) for its continued support of our registries and research studies, and to RESMO and NCI-AIIMS, Jhajjar, for their support in making the 5th HCC Annual Meeting possible.

As we look ahead, HCC remains committed to strengthening collaborative research, generating high-quality evidence relevant to the Indian context, advancing education and capacity building, and ultimately improving the care and outcomes of patients with hematological cancers.

Thank you to all our institutional partners, investigators, nurses, data teams, patients, supporters, and collaborators for being an integral part of the HCC journey.

Warm regards,

Dr. Vikram Mathews

Director

HEMATOLOGY CANCER CONSORTIUM

Who are we

Hematology Cancer Consortium (HCC) is a multi center collaborative organization established to fulfil the long felt need of good quality, cooperative group data in hematological malignancies in India.

Vision

Hematology Cancer Consortium (HCC), is a multi-center collaborative academic organization established with the aim to improve knowledge, standardize cost-effective treatment strategies and promote regionally relevant research in hematological cancers.

Our Goals



Aggregate clinical data to support the advances in hematological malignancies



Develop evidence-based, locally relevant treatment protocols and guidelines



Conduct investigator initiated prospective collaborative clinical trials addressing regionally relevant questions and evaluating cost effective treatment strategies



Continuous education to improve awareness and enhance knowledge of therapeutic options for standardization of care in hematological cancers

Our Institutional Partners

*We began with 12 leading Cancer Centers as our institutional partners
and we currently have 36 partners.*



Registry

One of our goals is to aggregate clinical data to support and advance care outcomes of hematological malignancies.

REGISTRIES:

REGISTRY	TOTAL RECORDS
Acute Myeloid Leukemia	10315
Acute Lymphocytic Leukemia	8254
Acute Promyelocytic Leukemia	1443
Chronic Myeloid Leukemia	6001
Lymphoma	16967
Myeloproliferative Neoplasm	189
Myelodysplastic Syndromes	164

We continue to focus on identifying existing challenges in hematological cancer care and developing appropriate solutions.


In 2025, our registries captured comprehensive data from centers across India, strengthening our understanding of disease patterns and treatment outcomes. The following pages present an overview of records added this year, along with year-wise contributions from participating centers since 2018.

Acute Myeloid Leukemia (AML) Registry

Progress in Acute Myeloid Leukemia
Registry from 2018 to 2025.

Chair: Dr. Smita Kayal

Co-Chair: Dr. Uday Kulkarni




Acute Lymphoblastic Leukemia (ALL) Registry

Progress in Acute Lymphoblastic Leukemia
Registry from 2018 to 2025.

Chair: Dr. Prasanth Ganesan

Co-Chair: Dr. Hasmukh Jain




Acute Promyelocytic Leukemia (APML) Registry

Progress in Acute Promyelocytic Leukemia
Registry from 2018 to 2025.

Chair: Dr. Prasanth Ganesan

Co-Chair: Dr. Hasmukh Jain




Chronic Myeloid Leukemia (CML) Registry

Progress in Chronic Myeloid Leukemia
Registry from 2020 to 2025.

Chair: Dr. Aby Abraham

Co-Chair: Dr. Sanjeevan Sharma




Lymphoma (LYM) Registry

Progress in Lymphoma Registry from 2020 to 2025.

Chair: Dr. Anu Korula

Co-Chair: Dr. Chandran Nair




Myeloproliferative Neoplasm (MPN)

Progress in Myeloproliferative Neoplasm Registry from 2024 to 2025.

Chair: Dr. Joseph John

Co-Chair: Dr. Chepsy Philip




Myelodysplastic Syndromes (MDS)

Progress in Myelodysplastic Syndromes Registry from 2024 to 2025.

Chair: Dr. Joseph John

Co-Chair: Dr. Chepsy Philip



Research

In 2025, HCC's research program demonstrated the power of collaborative science, uniting data from our national registries with the expertise of our Disease Working Groups. We advanced studies that address priority questions across the spectrum of hematological malignancies.

Each project is grounded in real-world evidence from our registries, ensuring that findings are both regionally relevant and practical for day-to-day clinical care. Our research aims to improve survival, reduce treatment related toxicity, and develop cost-effective strategies that can be implemented across diverse healthcare settings in India.

The following pages highlight our ongoing, upcoming, and completed studies, showing how registry-driven science is shaping treatment protocols, improving patient outcomes, and earning global recognition for Indian hematology research.

• Our Research Focus •



Ongoing Research Studies

Study Title: Phase III open labelled randomized controlled study to evaluate the optimal dose of all-trans retinoic acid in the treatment of acute promyelocytic leukemia (HCC-APL22 DOSA Study)

Study Design: Phase III open labelled randomized controlled trial

Study Duration: 7 years

Sample Size: 280 patients (140 patients in each arm)

CTRI Registration: CTRI/2023/09/057990

Status: Enrollment is ongoing. A total of 58 patients have been enrolled, and efforts are ongoing to include additional centres

Study Title: A phase III randomized study to compare a risk-stratified and response-adapted strategy to ABVD regimen in adolescents and adults with advanced-stage Hodgkin lymphoma (ABVD Hodgkin's Study)

Study Design: Open-label, Phase III randomized study, comparison of two standard-of-care approaches, multi-centre

Study Duration: 4 years accrual, 3 years follow-up since the last patient is enrolled, and 10 years for the long-term follow-up phase since the last patient is enrolled

Sample Size: 200 patients

CTRI Registration: CTRI/2020/12/030132

Status: Patient recruitment has been completed. Long-term follow-up is ongoing

Study Title: A phase III randomized controlled trial comparing AVD plus low-dose nivolumab versus ABVD using a risk-adapted strategy in patients with newly diagnosed advanced-stage classical Hodgkin lymphoma (LoNAH Study)

Study Design: Phase III randomized controlled trial

Study Duration: 3 years

Sample Size: 280 patients (140 patients in each arm)

No. of Centres Participating: 6

CTRI Registration: CTRI/2024/03/063942

Status: Patient enrollment is ongoing

Study Title: A multicentre phase III randomized controlled trial to test the efficacy of targeted agents during induction and a response-adapted consolidation in adolescent and young adult patients with de novo acute lymphoblastic leukemia (TARGET Trial)

Study Design: Open-label, Phase III, multi-arm, randomized controlled study

Study Duration: Patient accrual over 3 years, followed by a minimum follow-up period of 3 years after completion of treatment of the last participant

Sample Size: 1,080 participants in total, including 812 participants in the B-ALL cohort and 268 participants in the T-ALL cohort

CTRI Registration: CTRI/2025/03/082015

Status: Patient enrollment commenced in 2025. The study is currently ongoing

Study Title: COVID-19 with Hematological Cancers Registry of India (CHCRI Study)

Study Design: Observational patient registry

Observational Model: Case-only, prospective and retrospective

No. of Centres Participating: 11 centres

Status: Patient enrollment has been completed, and 5-year follow-up data collection is ongoing. Initial data from the study have been published in the Blood Cancer Journal

Study Title: Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study (HCC pRISM-S)

Study Design: Prospective validation study

Study Duration: 4 years

No. of Centres Participating: 17 centres

CTRI Registration: CTRI/2020/07/026450

Status: Data analysis and manuscript work are ongoing

Study Title: Patterns of Care and Outcomes of Adults ≥ 40 Years of Age with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL): A Multicenter Registry Analysis from India (ALL above 40 Years)

Study Design: Observational retrospective study

Study Duration: January 2019 to January 2021

Sample Size: 261 patients

No. of Centres Participating: 12 centres

Status: Source data verification has been completed. Manuscript preparation and publication activities are ongoing. *The study was recently published in 2026*

Study Title: Impact of Consolidation Radiotherapy in Bulky Diffuse Large B-Cell Lymphoma by PET-Based Response Assessment (DLBCL Study)

Study Design: Observational retrospective study

Study Duration: 2019 to 2022

Sample Size: 1,455 patients

No. of Centres Participating: 11 centres

Status: Source data verification and data validation were completed. Data analysis and manuscript work are ongoing. *The study was recently published in 2026*

Study Title: Stratifying using Clinical and Genomics Data for Risk Evaluation in Less Intensive Therapy for Acute Myeloid Leukemia in the Elderly (SCORE-LIT Study)

Study Design: Observational study

Study Duration: 1 January 2020 to 31 January 2025

No. of Centres Participating: 21 centres

Status: The abstract was accepted for presentation at ASH 2025. Source data verification was completed

Study Title: Role of COnsolidative RADiotherapy in bulky and/or extra-nodal DLBCL (CORAD-DLBCL) with complete metabolic response (CMR) after R-CHOP regimen: A Randomized Controlled Trial (CORAD-DLBCL study)

Study Design: Randomized controlled trial

CTRI Registration: CTRI/2024/12/078804

Status: The study is ongoing. It has been circulated among institutional partners to invite participation

Study Title: Impact of Timely Initiation of Treatment, Post-Induction Treatment, Maintenance Therapy, and Completion of Treatment on Event-Free Survival (EFS) and Overall Survival (OS) in Adolescents and Young Adults with Acute Lymphoblastic Leukemia (ALL) Treated with the GMALL/BFM-Based Protocol in India (TIMELY Study)

Study Design: Observational retrospective cohort study

No. of Centres Participating: 24 centres

Status: The abstract was accepted for presentation at ASH 2025. Source data verification was initiated

Study Title: Evaluating Kidney Function in Long-Term Imatinib Therapy for CML Patients (KITE Study)

Study Design: Observational retrospective study

No. of Centres Participating: 9 centres

Status: Study documents were circulated to participating institutions, and enrollment is ongoing. The abstract was accepted for presentation at ASH 2025. Source data verification was initiated

Study Title: Indian Multicentric Pregnancy and Chronic Myeloid Leukemia Outcomes Tracking Study (IMPACT-CML Study)

Study Design: Observational retrospective study

No. of Centres Participating: 5 centres

Status: The abstract was accepted for presentation at ASH 2025. Source data verification was initiated

Study Title: Comparative evaluation of consolidation strategies subsequent to azacitidine plus venetoclax-based induction in AML patients: A retrospective analysis of Haematological Cancer Consortium (HCC) registry in India (AZA-VEN Study)

Study design: Observational retrospective study

Status: Data analysis was ongoing

Study Title: HCC Lymphoma Core Group: Retrospective Study Proposal – Outcome of T-Cell Non-Hodgkin Lymphoma from HCC Registry (T-NHL Study)

Study Design: Observational retrospective study

Status: The abstract was accepted for presentation at ASH 2025. Source data verification was initiated

Study Title: Nationwide Survey of Azacitidine-Venetoclax Use in Indian Patients with Acute Myeloid Leukemia: Variability in Practice and the Need for Standardization

Study design: Nationwide survey

Status: The survey has been completed. The data are being compiled and converted into a manuscript for publication

Completed Clinical Trials

Study Title: Evaluation of the Safety and Efficacy of Generic Low-Dose Dasatinib for Frontline Therapy in Chronic-Phase Chronic Myeloid Leukemia – A Multicenter Phase II Single-Arm Study (GLaD Study)

Study Design: Phase II, multicenter, investigator-initiated study

Study Duration: 2 years

Sample Size: 90 patients

CTRI Registration: CTRI/2020/10/028317

Status: The clinical study has been completed. The manuscript is complete, and publication is in process. The study enrolled 90 patients between October 2020 and September 2021

Publications

www.hemecancer.org/publication.php

Publications from 2025:

- Outcomes and prognostic factors in patients with Burkitt lymphoma/leukemia in adolescents and adults: an experience from hematology cancer consortium
Blood Cancer Journal
<https://www.nature.com/articles/s41408-025-01240-w>

The following studies were presented in the ASH Annual Meeting and expositions:

www.hemecancer.org/abstracts.php

- Vasudevan S, Korula A, Nayak L, Abraham M, Shetty A, Karunakaran P, et al. Real World Outcome of Nodal T Cell Non-Hodgkin Lymphoma from Hematology Cancer Consortium Registry in India. Blood. 2025 Nov 3;146(Supplement 1):7154.
- Philip C, Jain H, Ganesan P, Shetty A, Khadwal A, Karunakaran P, et al. Impact of Timely Initiation of Treatment, Post-Induction Treatment, Maintenance Therapy, and Completion of Treatment on Event-Free Survival (EFS) and Overall Survival (OS) in Adolescents and Young Adults with Acute Lymphoblastic Leukemia (ALL) Treated with the GMALL/BFM-Based Protocol in India (TIMELY Study). Blood. 2025 Nov 3;146(Suppl 1):8049.

- Sharma S, Kapoor R, Mishra K, Abraham A, Ghosh S, Jain A, et al. Long-term imatinib therapy leads to significant reduction in GFR. Blood. 2025 Nov 3;146(Supplement 1):2005.
- Singh S, Jain A, Ghosh S, Malhotra P, Khadwal A, Biswas S, et al. Impact-CML: Indian Multicentric Data Supporting Safe Pregnancy and Molecular Control in Women with Chronic Myeloid Leukemia. Blood. 2025 Nov 3;146(Supplement 1):2009.
- Philip C, Kulkarni U, Kayal S, Jain H, Shetty A, Prakash G, et al. Less-Intensive Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) in India: Real-World Adoption and Prognostic Utility of ELN-LI and ELN-2022 Classification. Blood. 2025 Nov 3;146(Supplement 1):2829.

Education & Training

HCC is committed to strengthening capacity across its network through structured education and skill-building programs for nurses and Data Entry Operators (DEOs). These initiatives enhance clinical competencies, improve the quality of registry data, and promote the standardization of care in hematological malignancies across India.

In 2025, our education program continued to expand, offering regular online sessions, workshops, and practical training opportunities, ensuring accessibility for all participating centers.

Nursing Webinars

Webinar recordings are available on our website:

<http://hemecancer.org/>

Register as a member to access recordings:

<http://hemecancer.org/webinar-recording.php>

The HCC nursing team launched an educational initiative to improve knowledge and skills. Since then, a total of 49 webinars have been conducted till December 2025. These sessions are scheduled on the last Tuesday of each month.

Thank you to the entire team for your continued efforts!

Nursing Webinars Conducted Since January 2025:

TOPICS

SPEAKERS

Treatment of Chronic Myeloid Leukemia: Understanding Chemotherapy Regimens	Dr. Suvir Singh, Associate Professor and Head, Dept of Hematology and SCT unit DMCH
Treatment of Multiple Myeloma: Understanding Chemotherapy Regimens	Dr. Asif Iqbal, Associate Professor, Dept of Medical Oncology, BBCI
Cryotherapy for High Dose Melphalan	Sister Amrita Gope, Senior Ward Incharge, Tata Medical Centre, Kolkata
Evidence-Based Nursing Practices in Bone Marrow Transplant Units	Sister Simranpreet Kaur, Nursing Officer, PGIMER
Infection prevention in Cancer Patients	Sister Jayshri Thakur, Senior Manager, Nursing Administration, Jaslok hospital, Mumbai
Case Studies on Multiple Myeloma: A panel discussion	Capt. Uzma Bano & Maj. Manju Lata, Nursing Officers, Dept of Hematology, Army Hospital R&R Delhi

TOPICS

SPEAKERS

Introduction to Anemia and its management	Ms. Gracinna J, Charge Nurse, Hemato-Oncology Ward, Christian Medical College, Vellore
Handling of PICC line catheter, central line catheter, central venous catheter and Hickman catheter	Ms. Rojaline Kar, Senior Shift Incharge, Dept HCT, Tata Medical Centre, Kolkata
Nursing Assessment in Hemato Oncology	Ms. Rupa Dey Dutta, Nursing Officer, Chittaranjan National Cancer Institute
Acute Complications after Allogenic HSCT	Mrs. Nadhiya G, Charge Nurse, BMT Unit, CMC Vellore
Challenges in Nursing Care in Paediatric Hemato-Oncology Patients.	Mrs. Amrita Gope, Senior Ward Incharge, Heamatopoietic Stem Cell Transplant Unit, Tata Medical Center, Kolkata
Guidelines for Attendants on Hygiene, Diet and Patient Care During a Bone Marrow Transplant Stay	Sister Simranpreet Kaur, Nursing Officer, PGIMER

Training of Data Entry Operators

DEO workshop training program recordings are now available on the HCC website:

<https://hemecancer.org/training-module.php>

We believe in delivering accurate and good-quality data. To encourage this, we have been organizing various training programs for our Data Entry Operators and conducting source data verification as data accrues to ensure the quality of the data generated, provide evidence for the integrity of data at the time of publication and to minimize missing data.

We assess and identify areas where the DEOs need training and accordingly offer customized training sessions.

TOPICS	SPEAKERS
MPN Registry training	Dr. Alok Shetty, Dr. Joseph John and Dr. Chepsy Philip
MDS Registry training	Dr. Arihant Jain and Dr. Punit Jain

Patient Support Group Meetings

Patient Support Group Session recordings are now available on the HCC website:

<https://www.hemecancer.org/support-group-meeting.php>

Patient information booklet for hematological cancers are available on the HCC website (We encourage patients, physicians & patient advocacy groups to utilize the resources)

English- <https://www.hemecancer.org/patient-education.php>

Hindi- <https://www.hemecancer.org/patient-education-in-hindi.php>

Marathi- <https://www.hemecancer.org/patient-education-in-marathi.php>

Malayalam- <https://www.hemecancer.org/patient-education-in-malayalam.php>

Kannada- <https://www.hemecancer.org/patient-education-in-kannada.php>

Launched in March 2023, the HCC Patient Support Group is central to our mission of improving outcomes in hematological malignancies by supporting the overall well-being of patients and caregivers. We believe that informed and connected patients are better equipped to manage their care journey.

Held on the third Saturday of each month, these expert-led online sessions offer practical guidance on disease management, nutrition, survivorship, and emotional well-being. By December 2025, 30 monthly sessions had been conducted, creating a trusted platform for learning, sharing, and mutual encouragement. We are deeply grateful to the experts who generously dedicate their time to guide and support patients and caregivers.

Patient Support Session Conducted Since January 2025:

TOPICS

SPEAKERS

Understanding Lymphoma: A type of blood cancer	Dr. Sreeraj Vasudevan
Understanding Multiple Myeloma: A type of blood cancer	Dr. Nikita Mehra
Role of Physiotherapy in Hematological Cancers	Dr. Manali Kamat
Psycho Oncology: Patient behind disease	Ms. S Raja Venkateswari
Nutrition Management in Hemat Oncology	Ms. Saba Shaikh
Understanding Myeloproliferative Neoplasms (MPN)	Dr. Alok Shetty
Understanding Myelodysplastic Syndrome (MDS)	Dr. Chepsy Philip
Hygiene and Infection control at home in hematooncology	Nurse Sayali Jadhav
Embracing Inner Healing through Yoga in your Cancer Care Journey	Mrs. Heena Joshi
Understanding Clinical Trials	Dr. Joseph John
Rising Beyond Cancer- Conversation with Survivors	Mr. Saket Yadav, Mr. Peer Junaid and Ms. Pooja Arora, Moderator- Mr. Bhagvan Mishra
How to deal with the side effects of chemotherapy through Nutrition	Mr. Saket Yadav, Mr. Peer Junaid and Ms. Pooja Arora, Moderator- Mr. Bhagvan Mishra

FIFTH ANNUAL MEET

Our Fifth Annual Meeting was successfully conducted at the National Cancer Institute, AIIMS, Jhajjar, in association with the Research and Education Society of Medical Oncology (RESMO).

It provided a comprehensive platform for:

- DEO training and capacity building to improve data accuracy across the AML, Lymphoma and ALL databases.
- A dedicated nursing workshop featuring expert sessions and hands-on training in CAR T-cell therapy, BMT, research, infection control and supportive care.
- Scientific updates and collaborative discussions across HCC Working Groups, highlighting research progress and future plans.
- Expert lectures, panel discussions and debates on advances in hematological malignancies, CAR T-cell therapy and stem cell transplantation.
- Patient stories and advocacy discussions emphasizing empathy, trust and patient-centred care.
- Research presentations and academic recognition, including oral abstracts and e-posters showcasing ongoing research and clinical advancements.

The meeting brought together hematologists, oncologists, pathologists, laboratory professionals, trainees, nurses, allied healthcare professionals, patient navigators and advocates, fostering continued learning, collaboration and advancement in hematological cancer care and research.



Financial report

Independent Auditor's Report

M. P. Chitale & Co.

Chartered Accountants

Harvam House, Ambalal Doshi Marg, Fort, Mumbai - 400 001 • Tel. : 2265 1186 / 2265 3023 / 24 • E-mail : office@mpchitale.com

INDEPENDENT AUDITOR'S REPORT

To the Members of

Hematology Cancer Consortium- Association (HCCA)

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of Hematology Cancer Consortium- Association (hereinafter referred to as "HCCA") ("the Company") having its registered office Shop no. 1A, Ground Floor, Deep Co-operative Housing Society Limited, Jerbai Wadia Road, Parel Bhoiwada, Mumbai, 400012, for the year ended March 31, 2026, which include the Balance Sheet as at that date and the Statement of Income and Expenditure for the period from April 01, 2025 to March 31, 2026 and Cash Flows Statement for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, and its surplus and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls; that were operating effectively for ensuring the accuracy and



completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or taken together, they could reasonably be expected to influence the economic decisions of users taken based on these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- i. Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- ii. Consider the internal control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls.
- iii. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- iv. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our



auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- v. Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide management with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

The Companies (Auditor's Report) Order 2020, issued by the Central Government of India in terms of Section 143 (11) of the Act is not applicable to the Company.

As required by Section 143(3) of the Act, we report that:

- a. We have sought and obtained all the information and explanations, which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b. In our opinion, proper books of account as required by law have been kept by the Company as far as it appears from our examination of those books.
- c. The Balance Sheet, the Statement of Income and Expenditure, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account
- d. In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e. On the basis of the written representations received from the directors as on April 01, 2025 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.
- f. With reference to the amendment dated June 13, 2017 in notification no. G.S.R 464(E) dated June 5, 2015 issued by Central Government with regards to section 143(3)(i) of the Act, the requirements with regard to internal financial controls over financial reporting is not applicable to the Company.
- g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations, which would impact its financial position.






- ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- iii. There were no amounts, which were required to be transferred to the Investor Education and Protection Fund by the Company.
- iv. The Management has represented that, to the best of its knowledge and belief, as disclosed in the note to the accounts 2(i), no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- v. The Management has represented, that, to the best of its knowledge and belief, as disclosed in the note to the accounts 2(i), no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- vi. The Company has not declared or paid any dividend during the year and has not proposed final dividend for the year.
- h. Based on our examination, which included test checks, the Company has used accounting software for maintaining its books of account for the financial year ended March 31, 2026 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the Software. Further, during the course of our audit based on our audit procedures performed, we did not notice any instance of the audit trail feature being tampered with.

For M. P. Chitale & Co.
Chartered Accountants
ICAI FRN: 101851W

Ashutosh Pednekar
Partner
ICAI M No.: 041037
UDIN: 26041037GVYWCZ9629
Place: Mumbai
Date: September 24, 2026

Balance sheet as at March 31, 2026

Hematology Cancer Consortium- Association			
Balance Sheet as at March 31, 2026			
Particulars	Note No.	(₹ in Hundred)	
		As at March 31, 2026	As at March 31, 2025
EQUITY AND LIABILITIES			
Sources of Funds			
(a) Corpus fund		-	-
(b) Reserves and Surplus	1	1,00,317.81	93,724.86
Current Liabilities			
(a) Other Current Liabilities	2	5,288.79	1,821.55
(b) Short-term provisions	3	340.80	298.40
Total		1,05,947.40	95,844.81
ASSETS			
Non-Current Assets			
(a) Property, Plant and Equipment	4	3,834.84	4,151.60
(b) Investments	5	-	1,035.75
(c) Other Non-Current Assets	6	2,151.23	14,671.60
Current Assets			
(a) Cash and Cash Equivalents	7	72,149.72	74,055.66
(b) Other current Asset	8	27,811.61	1,930.20
Total		1,05,947.40	95,844.81
Also see accompanying Notes to and forming part of the Financial Statements - Note 13			
As per our report attached. For M. P. Chitale & Co. Chartered Accountants Firm Regn. No.101851W		For and On behalf of the Board Hematology Cancer Consortium- Association CIN: U85100MH2020NPL335745	
			
 Ashutosh Pednekar Partner M No.: 041037 Date: September 24, 2026 Place: Mumbai	 Niyali Sutaria James Director DIN: 09428177 Date: September 24, 2026 Place: Mumbai	 Palani Thyagarajan Director DIN: 09428178 Date: September 24, 2026 Place: Mumbai	 Bhavisha Sudarshan Sanadhya Chief Executive Officer Date: September 24, 2026 Place: Mumbai

Statement of Income and Expenditure for the period ended March 31, 2026

Hematology Cancer Consortium- Association				
Statement of Income and Expenditure for the year ended March 31, 2026				
SR No	Particulars	Note No.	(₹ in Hundred)	
			For the Year ended March 31, 2026	For the Year ended March 31, 2025
I	Donations, Grants & Sponsorships	9	1,57,586.22	1,52,432.60
II	Other Income	10	7,480.06	2,005.73
III	Total Revenue(I + II)		1,65,066.28	1,54,438.33
IV	Expenses			
	Expenses on Objects of Section 8 Company	11	1,44,764.21	1,14,357.93
	Depreciation	4	1,146.76	1,192.25
	Administration Expenditure	12	12,562.36	10,374.98
	Total Expenses		1,58,473.33	1,25,925.16
V	Surplus Before Tax		6,592.95	28,513.17
VI	Tax Expense		-	-
	Current Tax		-	-
	Deferred Tax		-	-
VII	Surplus for the Period(V-VI)		6,592.95	28,513.17

Also see accompanying Notes to and forming part of the Financial Statements - Note 13

As per our report attached.

For M. P. Chitale & Co.

Chartered Accountants

Firm Regn. No.101851W

For and On behalf of the Board

Hematology Cancer Consortium- Association

CIN: U85100MH2020NPL335745



Ashutosh Pednekar


Ashutosh Pednekar

Partner

M No.: 041037

Date: September 24, 2026

Place: Mumbai

Niyati Sutar

Niyati Sutar James

Director

DIN: 09428177

Date: September 24, 2026

Place: Mumbai

Palani Thyagarajan

Palani Thyagarajan

Director

DIN: 09428178

Date: September 24, 2026

Place: Mumbai

Bhavisha Sanadhya




Bhavisha Sudarshan Sanadhya

Chief Executive Officer

Date: September 24, 2026

Place: Mumbai

Cash flow statement

Hematology Cancer Consortium- Association		
Cash Flow Statement for the Year ended March 31, 2026		
Particulars	(₹ in Hundred)	
	March 31, 2026	March 31, 2025
A. Cash flow from operating activities		
Surplus Before Tax	6,592.95	28,513.17
Adjustments for:		
Depreciation	1,146.76	1,192.25
Operating cash flows before changes in assets/liabilities	7,739.71	29,705.42
Changes in assets/liabilities		
Increase/(decrease) in other current liabilities	3,467.24	(4,986.41)
Increase/(decrease) in short-term provisions	42.40	(28,787.48)
(Increase)/decrease Long-term loans and advances	-	-
(Increase)/decrease in Other Non current Assets	12,520.37	(8,367.00)
(Increase)/decrease in short-term loans and advances and Other Current Assets	(25,881.42)	12,161.32
Cash generated from operating activities	(2,111.70)	(274.15)
Net cash flows generated from operating activities (A)	(2,111.70)	(274.15)
B. Cash flow from investing activities		
Purchase of Property, Plant and Equipment	(830.00)	(1,941.30)
Investment In Fixed Deposits	1,035.75	(1,035.75)
Net cash flow generated from investing activities (B)	205.75	(2,977.05)
C. Cash flow from financing activities		
Issue of share capital	-	-
Net cash flow generated from financing activities (C)	-	-
Net increase in cash and cash equivalents (A+B+C)	(1,905.95)	(3,251.20)
Cash and Cash Equivalents as at the beginning of the year	74,055.66	77,306.85
Cash and Cash Equivalents as at the end of the year	72,149.72	74,055.66
Also see accompanying Notes to and forming part of the Financial Statements - Note 13		
As per our report attached.		
For M. P. Chitale & Co. Chartered Accountants Firm Regn. No.101851W	For and On behalf of the Board Hematology Cancer Consortium- Association CIN: U85100MH2020NPL335745	
 Ashutosh Pednekar Partner M No.: 041037 Date: September 24, 2026 Place: Mumbai	 Niyati Sutaria James Director DIN: 09428177 Date: September 24, 2026 Place: Mumbai	 Palani Thyagarajan Director DIN: 09428178 Date: September 24, 2026 Place: Mumbai
	 Bhavisha Sudarshan Sanadhya Chief Executive Officer Date: September 24, 2026 Place: Mumbai	



Fixed Assets

Hematology Cancer Consortium- Association											
Notes Forming part of the Financial Statements											
Note 4 -Property, Plant and Equipment											
(₹ in Hundred)											
Description	Rate	Gross Block				Depreciation				Net Block	
		As on April 01, 2025	Additions during the year	Sales/Adj. during the year	As on March 31, 2026	Provided upto March 31, 2025	Deduction/Adjustment	Provided for the year	Total Upto March 31, 2026	As on March 31, 2026	As on March 31, 2025
Furniture	9.50%	2,602.70	-	-	2,602.70	541.88	-	247.26	789.13	1,813.57	2,060.82
Computer	31.67%	4,375.90	830.00	-	5,205.90	2,561.99	-	811.48	3,373.47	1,832.43	1,813.91
Equipments	19.00%	463.30	-	-	463.30	186.43	-	88.03	274.46	188.84	276.87
Total (A)		7,441.90	830.00	-	8,271.90	3,290.30	-	1,146.76	4,437.06	3,834.84	4,151.60
Previous Year		5,500.60	1,941.30	-	7,441.90	2,098.04	-	1,192.35	3,290.29	4,151.60	3,402.56
Total Assets		7,441.90	830.00	-	8,271.90	3,290.30	-	1,146.76	4,437.06	3,834.84	4,151.60



Schedules / Notes

Hematology Cancer Consortium- Association

Notes Forming part of the Financial Statements

Note 1 : Reserves & Surplus

Particular	(₹ in Hundred)	
	March 31, 2026	March 31, 2025
Opening Balance	93,724.86	65,211.69
Add: Surplus carried over to balance sheet	6,592.95	28,513.17
Total	1,00,317.81	93,724.86

Note 2 : Other Current Liabilities

Particular	(₹ in Hundred)	
	March 31, 2026	March 31, 2025
Sundry Creditors	3,288.23	947.85
TDS Payable	2,000.56	873.70
Total	5,288.79	1,821.55

Note 3 : Short-term provisions

Particular	(₹ in Hundred)	
	March 31, 2026	March 31, 2025
Provision for Expenditure	340.80	298.40
Total	340.80	298.40

Note 5 : Investments

Particular	(₹ in Hundred)	
	March 31, 2026	March 31, 2025
Fixed Deposits	-	1,000.00
Interest Accrued on Fixed Deposits	-	35.75
Total	-	1,035.75

Note 6: Other Non-Current Assets

Particular	(₹ in Hundred)	
	March 31, 2026	March 31, 2025
TDS Receivable	1,151.23	13,671.60
Rent Deposit	1,000.00	1,000.00
Total	2,151.23	14,671.60



[Handwritten signatures]

Hematology Cancer Consortium- Association

Notes Forming part of the Financial Statements

Note 7: Cash & Bank Balances

Particular	(₹ in Hundred)	
	March 31, 2026	March 31, 2025
Bank Balances in Savings Account with HDFC Bank	71,036.81	74,055.66
Fixed Deposits	1,000.00	-
Interest Accrued on Fixed Deposits	112.91	-
Total	72,149.72	74,055.66

Note 8: Other current Asset

Particular	(₹ in Hundred)	
	March 31, 2026	March 31, 2025
Grant paid in Advance	434.75	713.25
Grants & Sponsorships Receivable	-	200.00
TDS Receivable- Current	24,551.29	-
GST Receivable	2,530.76	1,016.95
Prepaid Expenditure	294.81	-
Total	27,811.61	1,930.20

Note 9: Donations, Grants & Sponsorships

Particular	(₹ in Hundred)	
	March 31, 2026	March 31, 2025
Grant	1,47,586.22	1,52,432.60
Sponsorship	10,000.00	-
Total	1,57,586.22	1,52,432.60

Note 10: Other Income

Particular	(₹ in Hundred)	
	March 31, 2026	March 31, 2025
Saving Bank Interest	2,077.71	1,778.44
Unutilised Grant Refund	5,145.19	-
FDR Interest	77.16	35.75
Other Income	1.50	-
Interest on Income tax refund	178.50	191.54
Total	7,480.06	2,005.73



Signature
BBS

Hematology Cancer Consortium- Association

Notes Forming part of the Financial Statements

Note 11: Expenses on Objects of Section 8 Company

Particular	(₹ in Hundred)	
	March 31, 2026	March 31, 2025
Research Activity	1,36,488.53	1,05,214.12
Professional Fees	5,628.91	6,808.01
Insurance	1,770.00	1,770.00
Payment to Auditor	653.48	365.80
Other Expenditure	223.29	200.00
Total	1,44,764.21	1,14,357.93

Note 12: Administration Expenditure

Particular	(₹ in Hundred)	
	March 31, 2026	March 31, 2025
MCA Filling Fees	-	4.00
Office Expenditure	198.12	390.21
Interest on TDS and PT	191.39	113.33
PT Payment	150.00	-
Bank Charges	-	2.53
GST Fees	-	2.50
Office Internet	53.64	98.98
Courior Charges	35.60	35.50
Rent	3,894.00	2,875.00
Misc Expenditure	12.32	-
Mobile Bill	63.60	57.41
Administration Professional Fee	7,489.24	6,475.00
Office Electricity Bill	200.20	204.00
Printing and Stationery	274.25	116.52
Total	12,562.36	10,374.98



[Signature]

BBS

Notes forming part of the financial statements as at the year ended March 31, 2026

Hematology Cancer Consortium-Association CIN No: U85100MH2020NPL335745 NOTES FORMING PART OF THE FINANCIAL STATEMENTS AS AT THE YEAR ENDED MARCH 31, 2026
--

Note 13

1. Corporate Information:

Hematology Cancer Consortium-Association (the Company) is a private company limited by guarantee registered under section 8 of the Companies Act, 2013 ("the Act"). The Company was incorporated on January 09, 2020. Object of the company is to initiate a web based online data collection platform for hematological cancers, bio-banking of samples from cases with hematological cancers in each of the participating centers, analyzing the respective data and plan prospective collaborative studies in the relevant field, facilitating basic scientific research to understand the biology of the disorders, developing common treatment protocols and specific guidelines for management of hematological cancers, disseminating the knowledge and information to the physicians, patients, volunteers and other sections of the society as may be deemed fit, facilitating access to standard care treatment for patients diagnosed with hematological cancers and to do all the related or supportive or ancillary activities with respect to hematological cancers.

2. Significant Accounting Policies:

a. Basis of Accounting

The financial statements of the Company have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) in compliance with the Accounting Standards prescribed under Section 133 of the Act and the relevant provisions of the Act. The financial statements have been prepared on accrual basis under the historical cost convention.

The Company is a Small and Medium size Company (SMC) as defined in the general instructions in respect of Accounting Standards notified under the Act. Accordingly, the Company has complied with the Accounting Standards as applicable to small and medium size Company.

b. Use of Estimates

The preparation of financial statements in conformity with Generally Accepted Accounting Principles require estimates and assumptions to be made that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities on the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and differences between actual results and estimates are recognized in the periods in which the results are known/materialize.



[Handwritten signature]

[Handwritten initials BSS and 12]

c. Revenue Recognition

Donations received towards Hematology Cancer Consortium-Association are considered as income when received. Grants and Sponsorship are recognized as income based on the respective contractual terms. Revenue is recognized when it is earned and no significant uncertainty exists as to its realization or collection.

d. Corpus Funds

Receipts in the form of voluntary contribution made with a specific direction to be treated as corpus are recognized as Corpus Funds.

e. Related party transactions

(₹ in Hundred)

Description of Relationship	Names of related parties	1-April-2025 to 31-Mar-2026	1-April-2024 to 31-Mar-2025
Key Management Personnel (KMP)	Professional Fee to Bhavisha Sanadhya – CEO	19,200.00	19,200.00

f. Income Tax

Current tax, if any is the amount of tax payable on the taxable income for the year as determined in accordance with the applicable tax rates and provision of the Income Tax Act, 1961. The Company is registered under section 8 of the Act. The Company is exempt from the payment of Income tax. No provision for taxation has been made in the accounts since the company is eligible for exemption under Section 11 read with Section 2(15) of the Income tax Act, 1961

g. Provisions, Contingent Liabilities & Contingent Assets

A provision is recognized when the company has a present legal obligation as a result of past events and it is probable that an out flow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions are not discounted to present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

h. Depreciation

Depreciation on property, plant and equipment is provided on the straight-line method at the rates reflective of the estimated useful life of the assets estimated by the management.



Handwritten signature and initials.

i. Utilisation of Borrowed funds and share premium

- The Company has not granted any advance/loans or investments or provided guarantee or security or the like to any other person(s) or entities with an understanding, whether recorded in writing or otherwise, to further lend/invest/provide guarantee or security or the like to any other person on behalf of the company.
- The Company has not received any funds from any person(s) or entities with an understanding, whether recorded in writing or otherwise, that the company shall further lend or invest or provide guarantee or security or the like in any other person on behalf of and identified by such person(s)/entities.

j. Previous year figures have been regrouped/reclassified wherever necessary, in order to make them comparable.

3. Details on Benami Property Held

No proceedings have been initiated or pending against the Company for holding any benami property under the Benami Transaction (Prohibition) Act, 1988 .

4. Borrowing from Banks and Financial Institutions on Security of Current Assets

The Company does not have any borrowing facilities taken from Banks or Financial Institution.

5. Willful Defaulter

The Company has not been declared as a wilful defaulter by any bank (as defined under the Companies Act, 2013), in accordance with the guidelines on wilful defaulter issued by the Reserve Bank of India.

6. Relationship with Struck Off Companies

The Company does not have any transaction with Companies struck off under section 248 of the Act or section 560 of the Companies Act, 1956.

7. Registration of charges or satisfaction with the Registrar of Companies

There are no charges or satisfaction yet/pending to be registered with the Registrar of Companies at the end of the year.

8. Compliance with number of layer Companies

The Company does not have any subsidiary Accordingly compliance with the number of layers prescribed under clause 87 of section 2 of the Act read with Companies (Restriction on number of Layers) Rules 2017 is not applicable.



Signature
BBS Jm

9. Financial Ratio

Sr. No.	Ratio	Numerator	Denominator	Current Period	Previous Period	% Variance	Reason for Variance
1	Current Ratio	Current Assets	Current Liabilities	NA	NA		
2	Debt Equity Ratio	Total Debts	Shareholder's Equity	NA	NA		
3	Debt Service Coverage Ratio	Earnings available for debt service	Debt Service	NA	NA		
4	Return on Equity (ROE)	Net Profit after taxes- preference Dividend	Average Shareholder's Equity	NA	NA		
5	Inventory Turnover Ratio	Cost of Goods sold or Sales	Average Inventory	NA	NA		
6	Trade Receivables Turnover Ratio	Net Credit Sales	Average Account Receivable	NA	NA		
7	Trade Payables Turnover Ratio	Net Credit Purchase/ Expenses	Average Trade Payable	NA	NA		
8	Net Capital Turnover Ratio	Net Sales	Working Capital	NA	NA		
9	Net Profit Ratio	Net Profit	Net Sales	NA	NA		
10	Return on Capital employed (ROCE)	Earnings before Interest and Taxes	Capital Employed	NA	NA		

- Current Ratio = Current Assets / Current Liability
- Debt-equity ratio = Total Debt/ Shareholder's Equity
- Debt service coverage ratio = Earnings available for debt service / Debt Service
- Return on equity ratio = Net Profits after taxes – Preference Dividend (if any) / Average Shareholder's Equity
- Inventory turnover ratio = Cost of goods sold OR sales / Average Inventory
- Trade receivables turnover ratio = Net Credit Sales/ Average Accounts Receivable
- Average trade debtors = (Opening + Closing)/2
- Trade payables turnover ratio= Net Credit Purchases/ Average Trade Payable
- Net capital turnover ratio = Net Sales/ Average Working Capital




Signature BSS *Signature*

Connect with us

HCC is deeply grateful to its individual & corporate supporters for their generosity.

You can join us on:



CONTACT US

EMAIL: ADMIN@HEMECANCER.ORG